For example, in a clinical trial that detected EGFR mutations in non-small cell lung cancer (NSCLC) patients, Punnoose et al. 36 had low concordance rates for CTCs with 1 in 8 samples matching the corresponding primary tumor. This evidence concerns the gene EGFR and neoplasm.